Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940410 | 0.89 | ATR (0.40) | ATRALDH1A1KDM4ELCKMAPK1 | |
| SCHEMBL18961363 | 0.88 | CYP17A1 (0.38) | ATRCYP17A1NAMPTMETAP1BRD9 | |
| SCHEMBL20169942 | 0.85 | CYP17A1 (0.38) | ATRALDH1A1CYP17A1NAMPTMETAP1 | |
| SCHEMBL18940388 | 0.82 | ATR (0.51) | ATRALDH1A1KDM4ELCKMAPK1 | |
| SCHEMBL27585072 | 0.82 | ATR (0.37) | ATRCYP17A1NAMPTMETAP1BRD9 | |
| SCHEMBL18940478 | 0.81 | ATR (0.41) | ATRALDH1A1KDM4ELCKMAPK1 | |
| SCHEMBL18961358 | 0.77 | CYP17A1 (0.37) | ATRCYP17A1NAMPTMETAP1BRD9 | |
| SCHEMBL34473073 | 0.75 | ATR (0.48) | ATRALDH1A1KDM4ELCKMAPK1 | |
| SCHEMBL25138307 | 0.74 | ATR (0.42) | ATRKDM4ELCKMAPK1ATM | |
| SCHEMBL21639702 | 0.74 | ERN1 (0.44) | ATRALDH1A1KDM4ELCKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | disclosed |
| CN-107922386-B | 1, 4-disubstituted imidazole derivatives | 大日本住友制药株式会社 | 2021-04-02 | — | — | CN | disclosed |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| EP-3312170-A1 | 1,4-DI-SUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | ATR 3411/4885ALDH1A1 278/4885KDM4E 1942/4885 |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | ATR 2666/4885ALDH1A1 625/4885KDM4E 2080/4885 |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | ATR 3411/4885ALDH1A1 278/4885KDM4E 1942/4885 |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | NR4A3, NR0B1, NR2C2 | ATR 3411/4885ALDH1A1 278/4885KDM4E 1942/4885 |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | NR0B1, NR4A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ATR 3401/4885ALDH1A1 258/4885KDM4E 1821/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | ATR 2666/4885ALDH1A1 625/4885KDM4E 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.